OVERVIEW
The incidence of nonalcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis (MASH), continues to rise globally along with an increase in obesity, type 2 diabetes, and other metabolic disorders. Patients at risk of NASH greatly benefit from early identification and intervention. Join us at this interactive, case-based symposium where you can see how your case management strategies compare with those of your peers. Don’t miss out!
GOAL STATEMENT
The goal of this activity is for learners to be better able to assess risk of fibrotic disease and make evidence-based treatment recommendations for patients with or at risk of nonalcoholic steatohepatitis (NASH).
LEARNING OBJECTIVES
Upon completion of this activity, participants will: Have increased knowledge regarding the [LIST][ITEM]Prevalence and risk factors for NASH/MASH[ITEM]Clinical data for new and emerging treatments for NASH/MASH[/LIST]Have greater competence related to [LIST][ITEM]Evaluating risk of fibrotic disease and NASH/MASH in patients with risk factors [/LIST] Demonstrate greater confidence in their ability to [LIST][ITEM]Include new and emerging NASH/MASH treatments into treatment strategies [/LIST]
ACCREDITATION STATEMENT
In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. [JALOGO] [MEDSCAPE]
[bold]For Physicians[/bold] Medscape, LLC designates this live activity for a maximum of 1.25 [italic][bold]AMA PRA Category 1 Credit(s)™[/bold][/italic]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hynes Convention Center
Room: 210
900 Boylston Street
Boston, MA, 02115
Presented for attendees of The Liver Meeting® 2023. This event/function is provided by Medscape Education and supported by Madrigal Pharmaceuticals. This is not an official event/function of the American Association for the Study of Liver Diseases.
Supported by an independent educational grant from [BOLD]Madrigal Pharmaceuticals[/BOLD]